Mioc Marius, Soica Codruta, Bercean Vasile, Avram Sorin, Balan-Porcarasu Mihaela, Coricovac Dorina, Ghiulai Roxana, Muntean Delia, Andrica Florina, Dehelean Cristina, Spandidos Demetrios A, Tsatsakis Aristides M, Kurunczi Ludovic
Faculty of Pharmacy, 'Victor Babes' University of Medicine and Pharmacy, Timisoara 300041, Romania.
S.C. SINOFIN S.R.L., Timisoara 300544, Romania.
Int J Oncol. 2017 Apr;50(4):1175-1183. doi: 10.3892/ijo.2017.3912. Epub 2017 Mar 14.
The extensive biochemical research of multiple types of cancer has revealed important enzymatic signaling pathways responsible for tumor occurrence and progression, thus compelling the need for the discovery of new means with which to block these signaling cascades. The phosphoinositide 3-kinase/ protein kinase B (PI3K/AKT) pathway, which plays an important role in maintaining relevant cellular functions, exhibits various alterations in common human cancers, thus representing a suitable target in cancer treatment. Molecules bearing the 1,2,4-triazole moiety are known to possess multiple biological activities, including anticancer activity. The current study used molecular docking in the design of 5-mercapto-1,2,4-triazole derivatives with antiproliferative activity targeting the PI3K/AKT pathway. Three structures emerged as the result of this method, which indicated for these a highly favorable accommodation within the active binding site of PI3K protein, thus acting as potential PI3K inhibitors, and hence interfering with the above-mentioned pathway. The molecules were synthesized and their chemical structure was confirmed. The antiproliferative activity of these compounds was tested on 4 cancer cell lines (A375, B164A5, MDA-MB-231 and A549) and on normal human keratinocytes (HaCaT) by in vitro alamarBlue assay. The 3 compounds revealed antitumor activity against the breast cancer cell line (MDA-MB-231) and reduced toxicity on the normal cell line. The antibacterial activity of the compounds was also tested in vitro on Gram-positive and Gram-negative bacterial strains, revealing moderate activity.
对多种癌症进行的广泛生化研究揭示了负责肿瘤发生和进展的重要酶促信号通路,因此迫切需要发现阻断这些信号级联反应的新方法。磷酸肌醇3激酶/蛋白激酶B(PI3K/AKT)通路在维持相关细胞功能方面发挥着重要作用,在常见人类癌症中表现出多种改变,因此是癌症治疗的合适靶点。已知含有1,2,4-三唑部分的分子具有多种生物活性,包括抗癌活性。本研究利用分子对接设计了针对PI3K/AKT通路具有抗增殖活性的5-巯基-1,2,4-三唑衍生物。该方法产生了三种结构,表明它们在PI3K蛋白的活性结合位点内具有高度有利的适应性,从而作为潜在的PI3K抑制剂,进而干扰上述通路。合成了这些分子并确认了它们的化学结构。通过体外alamarBlue测定法在4种癌细胞系(A375、B164A5、MDA-MB-231和A549)和正常人角质形成细胞(HaCaT)上测试了这些化合物的抗增殖活性。这3种化合物对乳腺癌细胞系(MDA-MB-231)显示出抗肿瘤活性,对正常细胞系的毒性降低。还在体外对革兰氏阳性和革兰氏阴性细菌菌株测试了这些化合物的抗菌活性,显示出中等活性。